Publications by authors named "Ana Lledo-Delgado"
Article Synopsis
- - Teplizumab is an approved treatment for delaying type 1 diabetes (T1D) in patients at risk, with recent studies revealing that 36% of participants were either undiagnosed or remained diabetes-free after 5 years, indicating potential operational tolerance.
- - Analysis of CD8+ T cells showed initial activation signs post-treatment, which reverted after 18 months, with reduced gene expression linked to T cell response in those who responded positively to the drug while showing increased exhaustion markers.
- - The study concluded that teplizumab helps promote operational tolerance in T1D by inducing T cell exhaustion and preventing the growth of autoantigen-reactive T cells over time.
Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood cells before and after teplizumab treatment.
View Article and Find Full Text PDF